How Much Does Enbrel Cost in 2026?

Enbrel (etanercept) is a self-injected biologic for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Medicare's negotiated price took effect on January 1, 2026: $2,355 for a 30-day supply, 67% below the $7,106 list price. The other thing worth knowing is that two Enbrel biosimilars have been FDA-approved for years and still cannot be sold in the United States until 2029.

  • Medicare's negotiated price is $2,355 per 30-day supply, in effect since January 1, 2026, down from a $7,106 list price.
  • Two biosimilars, Erelzi (approved 2016) and Eticovo (approved 2019), have never launched here. Patents and an injunction keep them off the US market until about April 2029.
  • On a specialty tier with coinsurance you are likely to reach the $2,100 annual Part D cap within the first two fills, after which covered drugs cost you nothing for the rest of the year.
  • Unlike most biologics on this list, Enbrel is dispensed through a pharmacy rather than infused, so it runs through Part D, not Part B.

What You Actually Pay

Figures are for a 30-day supply. List and negotiated prices are from CMS; what you pay depends on your coverage.

Your situationTypical cost
Medicare negotiated price, 2026$2,355 / 30 days
Medicare Part D, your shareup to $2,100 / year
Commercial insurancecopay or coinsurance
Uninsured, cash~$7,106 (list)

The Biosimilars Exist, Are Approved, and You Cannot Buy Them

This is the clearest example in the whole program of why an approval is not an option. The FDA approved Erelzi in 2016 and Eticovo in 2019, finding both highly similar to Enbrel with no clinically meaningful differences. Neither has ever been sold in the United States. Amgen obtained a later patent that extended exclusivity well past the original 2012 expiry, and both biosimilars sit under injunction until roughly April 2029.

In other countries etanercept biosimilars have been competing for years and prices fell accordingly. In the US the negotiated $2,355 is, for now, the substitute for that competition. If someone tells you to ask your doctor about a cheaper etanercept biosimilar, there is nothing to prescribe. What you can ask about is a different biologic class entirely, where biosimilars are available, and that is a clinical conversation rather than a pricing one.

What Medicare's Negotiated Price Does, and Does Not, Change

The headline number is not your copay.

$2,355 is the maximum fair price, the amount Medicare and your Part D plan pay for a 30-day supply of Enbrel. What you are charged at the counter is still set by your plan's tier and cost-sharing rules.

It helps you directly if you pay coinsurance

Many plans charge a percentage of the drug's price on brand and specialty tiers. If you owe 25% of $7,106, that is far more than 25% of $2,355. When your share is a percentage, a lower negotiated price lowers your bill directly.

It may not change a flat copay

If your plan charges a fixed dollar copay for that tier, your copay can stay the same even though the plan is paying less. The benefit then shows up in the program's overall costs rather than your receipt.

It changes how fast you hit the cap

Your spending counts toward the $2,100 annual Part D out-of-pocket cap in 2026. A cheaper drug means a smaller share each month, which can mean you reach the cap later or not at all, so the year-end picture differs from past years.

It does not change coverage rules

A negotiated price does not force a plan to cover Enbrel, drop prior authorization, or change its tier. Plans still set their own formularies, so check yours before you assume the new price applies to you.

Because tiers and cost-sharing vary so much between plans, the only way to know your real cost is to check Enbrel against each plan's formulary. If you would rather have that done for you, our Find My Medicare Plan service checks your specific drugs against the plans available to you for a flat $99.

Is There a Generic for Enbrel?

Not in a way you can use. Erelzi (etanercept-szzs, approved 2016) and Eticovo (etanercept-ykro, approved 2019) are FDA-approved biosimilars that have never been marketed in the United States, blocked by patents and an injunction until about April 2029. There is no generic or biosimilar etanercept available at a US pharmacy today. Biosimilars do exist for other biologics used in the same conditions, which is worth raising with your prescriber.

Does Insurance Cover Enbrel?

Usually, with conditions

Enbrel is covered by Medicare Part D and most commercial plans, almost always on a specialty tier with coinsurance, and prior authorization and step therapy are standard. Many plans require you to try a cheaper biologic or a conventional DMARD such as methotrexate first. Because it is pharmacy-dispensed rather than infused, it falls under your drug benefit, so the Part D out-of-pocket cap applies.

If you are denied or moved a tier

A denial is not the end, and a tier change at renewal is not either. Your prescriber can submit a letter of medical necessity or a formulary exception, and you have formal appeal rights. See how to appeal an insurance denial and what to do when a plan drops your drug.

How to Pay Less

On commercial insurance, use the Enbrel Support copay program

Amgen runs a copay assistance program that can reduce a commercial copay substantially. By law it cannot be used with Medicare, Medicaid or any other federal coverage.

Ask whether a different biologic class fits

Etanercept biosimilars are unavailable, but biosimilars are on the market for other biologics used in rheumatoid arthritis and psoriasis, and many plans prefer them. Whether a switch is appropriate is a decision for you and your prescriber, not a cost decision, but it is a fair question to raise.

On Medicare, check Extra Help and the payment plan

Extra Help (the Low Income Subsidy) sharply reduces Part D costs and its income limits are higher than most people expect. The Medicare Prescription Payment Plan can also spread your Part D costs evenly across the year instead of front-loading them, and you opt in through your plan.

Check the tier before you commit to a plan

The same drug can cost very different amounts across plans in the same ZIP code. During open enrollment, compare Enbrel on each plan's formulary, and remember the plan that was cheapest last year may not be this year.

Push back on a bill you have already received

If you were billed more than you expected, or a claim was processed wrong, CareRoute Bill Defense reviews and disputes medical bills, with no fee unless we save you money.

Not sure which plan covers Enbrel best?

For a flat $99, we research the Medicare plans available to you and check them against your specific drugs and doctors, then hand you a clear comparison. We are independent, sell no insurance, and take no commissions.

Frequently Asked Questions

Is there a biosimilar or generic for Enbrel?

Two biosimilars are FDA-approved, Erelzi (etanercept-szzs, 2016) and Eticovo (etanercept-ykro, 2019), but neither has ever been sold in the United States. Amgen secured a later patent extending exclusivity, and both products are under injunction until around April 2029. So there is nothing cheaper in etanercept for your pharmacist to substitute. Biosimilars are available for other biologics used in the same conditions, which is a question for your prescriber.

Is Enbrel covered under Medicare Part B or Part D?

Part D. Enbrel is a self-injected drug you pick up from a pharmacy, so it runs through your Medicare drug plan rather than your medical benefit. That matters because Part D has an annual out-of-pocket cap, $2,100 in 2026, while Part B does not. Infused biologics given in a clinic are usually billed to Part B at 20% coinsurance with no cap, which is why the same condition can cost very different amounts depending on how the drug is delivered.

What is Medicare's negotiated price for Enbrel?

Medicare negotiated a maximum fair price of $2,355 for a 30-day supply of Enbrel, effective January 1, 2026. That is 67% below the $7,106 list price CMS used as the comparison. Enbrel was one of the first ten drugs in the Medicare Drug Price Negotiation Program, selected because it was among the highest-spending Part D drugs without generic or biosimilar competition at the time. The price applies automatically at the pharmacy for Part D members.

Will the negotiated price lower what I actually pay for Enbrel?

It can, but it is not your new copay. The maximum fair price is what Medicare and your Part D plan pay the pharmacy, not automatically what you are charged. If your plan charges coinsurance, a percentage of the drug price, a lower negotiated price lowers your share directly. If your plan charges a flat copay for that tier, your copay may not change at all. Either way, your total Part D out-of-pocket is capped at $2,100 in 2026, after which covered drugs cost you nothing for the rest of the year.

Does insurance cover Enbrel?

Generally yes. Enbrel is covered by Medicare Part D and most commercial plans, though plans commonly require prior authorization and sometimes step therapy, meaning you try a cheaper option first. The tier it sits on, not whether it is covered, is usually what decides your cost, and the same drug can sit on different tiers in two plans sold in the same ZIP code. Check your plan's formulary for the tier and any restrictions before you fill it.

Related

Sources

  • CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (maximum fair price and list-price comparison)
  • CMS / Medicare.gov (Part D out-of-pocket cap, $2,100 in 2026, and the $615 maximum deductible)
  • FDA Orange Book and Purple Book (approval and substitutability status for etanercept)
  • Amgen published list price and patient-support program terms

Prices are national figures for a 30-day supply at a common dose and vary by pharmacy, dose, and plan. List prices are the figures CMS published as its negotiation comparison. This page is educational and is not medical or financial advice: do not start, stop, or switch a prescription on the basis of price without talking to your prescriber. Last updated November 20, 2026.